scout

Shorts

Michael Barish, PhD, discussed the application of a scorpion venom-derived chlorotoxin in treating 4 patients with glioblastoma in an interview with CancerNetwork.
1:01
Exploring The Applicability of Scorpion Venom in Glioblastoma Treatment
4 months ago
by
Michael Barish, PhD
Toru Kondo, PhD, discussed his presentation titled, "Evaluating EVA1-ADC as a Novel Therapeutic Strategy for Eliminating Glioblastoma-Initiating Cells," that he gave at World ADC
0:54
EVA1-Targeting ADCs May Reduce AEs vs Anti-CD133 Agents in Glioblastoma
4 months ago
by
Toru Kondo, PhD
ADCs May Be Emerging As Preferred Backbone in HER2+/HR+ Breast Settings
0:44
ADCs May Be Emerging As Preferred Backbone in HER2+/HR+ Breast Settings
4 months ago
by
Aditya Bardia, MD, MPH, FASCO
Patients with medullary thyroid carcinoma or the MEN type 2 genetic disorder should not start GLP-1 agents for risk of insulin secretion and severe hypoglycemia.
0:37
When Should Patients with NETs Be Advised Not To Take GLP-1 Agents?
4 months ago
by
Joseph Dillon, MB, BCh, BAO
Micheal C. Soulen, MD, discussed his presentation of the phase 2 CapTemY90 trial assessing the combination of radioembolization and chemotherapy in patients with liver-dominant NETs at the 2025 North American Neuroendocrine Tumor Symposium.
0:37
Y90/Radiosensitizing Chemotherapy Regimen Feasible in Liver-Dominnat NETs
4 months ago
by
Michael C. Soulen, MD
In an interview with CancerNetwork®, Eyub Akdemir, MD, radiation oncologist at Miami Cancer Institute, discussed findings from a single-institution retrospective study evaluating the timing and predictors of severe lymphopenia in patients with lung cancer treated with definitive proton chemoradiotherapy.
0:55
Proton Chemoradiotherapy May Reduce Severe Lymphopenia Rates
4 months ago
by
Eyub Akdemir, MD
CancerNetwork spoke with Udhayvir S. Grewal, MBBS, assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, about an analysis of the Neuroendocrine Tumors - Patient-Reported Outcomes (NET-PRO) study he presented at the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium.
0:44
NET-PRO: Younger NET Population Experiences More Significant AEs
5 months ago
by
Udhayvir S. Grewal, MD
CancerNetwork® spoke with Mary Maluccio, MD, MPH, FACS, about her presentation on a PRRT–naive cohort of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who received the investigational SSTR–targeted alpha therapy 212Pb-DOTAMTATE at NANETS.
0:39
Examining 212Pb-DOTAMTATE Clinical Outcomes in PRRT-Naive GEP-NETs
5 months ago
by
Mary Maluccio, MD, MPH, FACS
According to Stefano Partelli, MD, PhD, quality metrics in pNET surgery are fundamentally tied to the experience and volume of the treating center, given the high risk of complications and mortality.
1:13
Predicting Early Post-Surgical Recurrence in pNETs
5 months ago
by
Stefano Partelli, MD, PhD
Julie Hallet, MD, MSc, FRCSC, stated that the core mission of initiatives like CUTNETs is to standardize care and mitigate the high risks associated with complex operations on neuroendocrine tumors.
1:06
CUTNETs: Spotlighting a Collaboration Between Surgery and NET Oncology
5 months ago
by
Julie Hallet, MD, MSc, FRCSC
Twelve patients in the CARTITUDE-1 trial maintained a cancer-free, MRD-negative status for 5 years without maintenance, fulfilling a proposed curative definition for a "cure".
0:59
Including "Cure" in the Multiple Myeloma Treatment Dialogue
5 months ago
by
Sundar Jagannath, MD
David Rimm, MD, PhD, said that pathologists play a crucial role in educating oncologists about the "science behind the assay," helping oncologists understand the robustness, sensitivity, and specificity of different tests, which can have varying levels of accuracy and precision.
0:39
Looking Beyond Genomics in Precision Medicine for Cancer Care
6 months ago
Elizabeth Kessler, MD highlighted a new target that oncologists should be aware of: the combination of niraparib, abiraterone, and prednisone in combination with an ADT backbone. which has shown a progression-free survival benefit and a trend toward an overall survival benefit.
1:29
Spotlighting Imaging/Therapuetic Advances Hormone Sensitive Prostate Cancer
6 months ago
by
Ben Garmezy, MD(+1 more)
Dosing Considerations for Optimizing Ruxolitinib Efficacy in Myelofibrosis
0:30
Dosing Considerations for Optimizing Ruxolitinib Efficacy in Myelofibrosis
6 months ago
by
Francesca Palandri, MD, PhD
Manojkumar Bupathi, MD, MS, executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute, spoke with different experts about their localized therapy perspectives during the morning sessions from World GU.
1:22
Highlighting Advances in Localized Therapy for Genitourinary Cancers
6 months ago
by
Manojkumar Bupathi, MD, MS(+3 more)
Kerry R. Schaffer, MD, assistant professor in the Department of Medicine at the Vanderbilt Ingram Cancer Center and genitourinary oncologist, discussed the evolving role of radioligand therapy and imaging criteria in prostate cancer at the 2025 World Conference on Genitourinary Cancers.
1:02
Advancing Radioligand Therapy and Imaging Criteria in Prostate Cancer
6 months ago
by
Benjamin Garmezy, MD(+1 more)
In patients with ES-SCLC, a population that has historically had limited treatment options after initial platinum-based chemotherapy, the recent accelerated approval of tarlatamab marks a significant advancement.
0:53
Offering Hope for Relapsed Brain Metastatic ES-SCLC With Tarlatamab
6 months ago
by
Bingnan Zhang, MD, MBA
Although more recent drugs with a different mechanism of action are continuing to improve the treatment landscape, there is still work to be done to improve quality of life and achieve a cure for patients with chronic myeloid leukemia.
0:35
Outlining Chronic Myeloid Leukemia Advancements Through the Decades
6 months ago
by
Jorge E. Cortes, MD
A multidisciplinary discussion may help in developing optimal treatment strategies for genitourinary cancers cases not covered by standard guidelines.
1:30
Optimizing Care Through Multidisciplinary Collaboration in GU Cancers
6 months ago
by
Benjamin Garmezy, MD(+1 more)
Ronald Bleday, MD, colorectal surgeon, touched upon his experience with an Enhanced Recovery after Surgery perioperative approach for pain management for patients with colorectal cancer.
0:34
Managing Narcotic Use in Perioperative CRC Care
7 months ago
by
Ronald Bleday, MD
Michael William Kendall, MD, a primary care physician specializing in cancer survivorship, emphasized the importance of timely discussions surrounding sexual health.
1:30
Discussing Sexual Health in Oncologic Practice
7 months ago
by
Micheal William Kendall, MD
While weight loss can be a compelling factor for a cancer diagnosis, Denise B. Reynolds, RD, does not promote weight loss during active treatment, instead, focusing on helping patients maintain their weight and nutritional status.
1:17
Managing Cancer-Related Adverse Effects Through Nutrition and Wellness
7 months ago
by
Denise B. Reynolds, RD
McFarland emphasized the need for a new approach, moving past the "see one, do one, teach one" model common among many oncologists.
1:19
Bridging the Psycho-Oncology Gap in Body Image Management
7 months ago
by
Daniel C. McFarland, DO
Michelle Fingeret, PhD, suggests humanizing language in patients who may be experiencing body image concerns following cancer treatment.
1:29
Challenging Negative Body Image Language in Psycho-Oncology
7 months ago
by
Michelle Fingeret, PhD
In a recent interview with CancerNetwork, Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, expressed her delight and humility at being named leader of the Northwell Health Start Center for Cancer Research Unit.
1:16
Expanding Early Phase Trial Access Through START
7 months ago
by
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD